Topica Raises $27M Series B For Nail Antifungal Trial
By Tom Wall
Wednesday, October 19, 2011
There's a lot of toenail and fingernail fungus among us, enough that Topica Pharmaceuticals Inc., has raised $27 million in a Series B financing to support a Phase IIb/III trial of the privately held Palo Alto, Calif.-based biotech's luliconazole topical antifungal agent for treatment of onychomycosis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.